Epithalon Without Prescription: The Nominator Withdrew It

Epithalon without prescription is not a loophole, a workaround or a grey market as those words are usually meant. It is the only channel that exists, because the channel a prescription would run through was never built.

That distinction is worth the page. A reader who believes there is a legitimate medical route they are being denied will go looking for one, and will find sellers happy to imply they represent it. A reader who understands why no such route exists is a better judge of the one that does. The evidence for all of this is public, it sits on two FDA documents, and it is misreported almost everywhere.

The listing this page refers back to:

Epithalon without prescription: three channels, and which of them exist

Every peptide reaches a buyer through one of three routes. For this compound, two of them are closed, and knowing which two is the whole of the legal picture.

The third row is where the market lives, and it is a genuinely different kind of transaction from the first two rather than a discounted version of them. There is no prescriber reviewing suitability, no pharmacist checking anything, no dispensing record and no route by which an adverse event would be collected and acted on. The compensating feature, and it is a real one, is that the material arrives with an analytical document attached, which is more than most consumer purchases come with. We describe what those terms commit a buyer to in general in our explanation of what research-use supply actually means.

What FDA published, word for word

The agency’s page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, contains one paragraph on this compound. It is short enough to quote in full, and quoting it in full is the point, because paraphrases of it circulate with the qualifications stripped out.

Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.

Read carefully, that is not a finding of harm. It is a statement about an empty file. The word may is doing work in the first sentence, the phrase has not identified is doing work in the second, and lacks sufficient information is doing work in the third. Nobody has shown FDA that this compound is dangerous. Nobody has shown FDA that it is not. The agency is describing the size of the gap it is looking at.

Which is why the standard sales rebuttal, that FDA has never demonstrated any harm from epitalon, is technically accurate and completely beside the point. The same document says the same thing about the other direction. An absence of evidence pointing one way is not evidence pointing the other, and a compound whose file is empty is not a compound that has been cleared.

Withdrawn by the nominator is not refused by the agency

The status of this compound has three states and most sources report the wrong one. Here is the sequence, as the FDA documents record it.

• Nominated. Somebody proposed epitalon for the section 503A bulks list, which is the mechanism by which a substance with no approved product behind it can legally be compounded from bulk.
• Placed in category 2 under the interim policies. That is the bucket for nominated substances that raise significant safety concerns while the agency works through them. It is a flag, not a verdict.
• Withdrawn.Epitalon now appears in the agency’s table of bulk drug substances nominated but withdrawn, which FDA describes as substances previously in category 2 of the interim policies that were withdrawn by the nominators. The withdrawal was the nominator’s act. FDA did not issue a refusal.
• Absent. The section 503A category list updated on 14 May 2026 sorts nominated substances into category 1, category 2 and category 3. Epitalon is in none of them. Today it sits on no category list at all.

The tense matters more than it sounds. Epitalon was placed in category 2 is stale but defensible. Epitalon is category 2 is wrong, and it is the sentence you will find on vendor pages, because it sounds like an official status and reads as a form of recognition. The accurate statement is duller and less flattering: nothing on FDA’s current lists mentions this compound, and the process that would have produced a listing was abandoned before it concluded.

The identical sequence applies to the other two Russian peptides this site covers, which is not a coincidence: they came through the same nomination process and left it the same way. We set the same chronology out, with the differences that matter, in our account of the Semax regulatory position and our account of the Selank one.

The concern is analytical, and a certificate answers part of it

FDA names two mechanisms, and both of them are laboratory questions rather than clinical ones. That is unusual and it is useful, because it means a batch document can speak to part of the regulator’s stated worry.

Peptide-related impurities are the by-products of synthesis: truncated sequences where a coupling step failed, deleted sequences missing a residue, modified sequences where a protecting group did not come off cleanly. They are chemically similar to the target and biologically different from it. Reversed-phase chromatography separates them by hydrophobicity and a diode-array detector at 214 nm sees the peptide bond itself, so they show up as their own peaks. This is exactly what the purity figure on a certificate grades.

Aggregationis different in kind, and this is where the honest answer gets uncomfortable. Aggregates are not impurities; they are the correct molecules associated into particles. The published literature on therapeutic protein aggregates treats their immunogenic potential as a function of particle size, count and handling history, and FDA’s own guidance on immunogenicity assessment treats aggregation as a product-quality attribute to be characterised in its own right. The methods that address it are size-exclusion chromatography and subvisible particle counting, and neither of them is a reversed-phase purity assay.

Against that framework, here is what the certificate for batch 15-05260628 does and does not cover. It reports purity at 99.312 percent by reversed-phase chromatography against a specification of greater than 98 percent, which addresses the impurity half of FDA’s concern directly. It confirms identity by liquid chromatography with mass spectrometry. It records an endotoxin safety screen passed against a limit of 0.5 EU/mL or below, a microbial sterility screen returning no growth, four heavy metals returning negative, and net content at 9.64 mg against a 10 mg label with a stated 10 percent tolerance, which is inside tolerance and under the label.

It carries no size-exclusion result and no particle count. So of the two mechanisms FDA names, this document speaks to one and is silent on the other. That is not a criticism of the laboratory, which reported what it was asked to run, and it is a stronger document than most in this market. It is a limit on what the document can be used to argue, and a page that quoted the purity figure as an answer to the immunogenicity concern would be overstating it by half.

The third element of FDA’s paragraph is untouched by any of it. No assay establishes whether a substance harms a human, and the agency’s point is that the human data do not exist. A complete certificate and an empty clinical file are compatible states, and this compound is in both of them at once.

What is claimed for it, and by whom

It would be incomplete to describe the regulatory gap without describing what fills it commercially. Epithalon is a synthetic tetrapeptide, four residues, Ala-Glu-Asp-Gly, PubChem CID 219042, formula C14H22N4O9, molecular weight 390.35. FDA and PubChem spell it Epitalon and the buying market spells it Epithalon; the CAS number 307297-39-8 settles that they are one molecule. It was developed in Russia from a pineal extract, and it is sold on claims about telomeres, telomerase and longevity.

Those claims trace overwhelmingly to one research group in St Petersburg, publishing over several decades, in journals with limited international visibility and often in Russian. One of that group’s papers is titled as a statement that pineal and thymic peptides prolong human life. Reporting that a paper with that title exists is accurate. Treating it as an established finding is not, because it is not a registered controlled trial, it was not independently replicated in the form its title implies, and the outcome it names is the single hardest endpoint in medicine to establish. This site reports what is claimed and who claims it. It does not adopt those claims, and nothing here should be read as saying that this compound extends human life.

The regulator’s position and the seller’s position are therefore not in conflict on the facts, only on the emphasis. Both agree there is no approval. Both agree there is no controlled human outcome evidence. One treats that as a reason for caution and the other treats it as an absence of any finding against. A buyer reading a certificate should be clear which question the document is answering, and it is not that one. The per-milligram arithmetic that the same certificate does settle is in our breakdown of what an Epithalon milligram costs.